Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study.
about
Antihypertensive agents for preventing diabetic kidney diseaseAntioxidant supplements for preventing gastrointestinal cancersAntioxidant supplements for prevention of mortality in healthy participants and patients with various diseasesAntioxidant supplements for preventing gastrointestinal cancersThe HOPE (Heart Outcomes Prevention Evaluation) Study and its consequencesCentral obesity associates with renal hyperfiltration in the non-diabetic general population: a cross-sectional studyAlbuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survivalMicroalbuminuria is a predictor of chronic renal insufficiency in patients without diabetes and with hypertension: the MAGIC study.A gene variant in CERS2 is associated with rate of increase in albuminuria in patients with diabetes from ONTARGET and TRANSCEND.Prevalence, risk factors and awareness of albuminuria on a Canadian First Nation: a community-based screening study.Why do young people with chronic kidney disease die early?Cystatin C and albuminuria as risk factors for development of CKD stage 3: the Multi-Ethnic Study of Atherosclerosis (MESA)Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset.Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective.Familial clustering of risk factors for cardiovascular disease among first-degree relatives of patients with chronic kidney disease in a sub-Saharan African population.Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk.The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney diseaseRenin-angiotensin-aldosterone system-mediated redox effects in chronic kidney diseaseAre renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.A guide to the management of blood pressure in the diabetic hypertensive patient.Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians.Identification and management of albuminuria in the primary care setting.Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.Metabolic syndrome and microalbuminuria predict renal outcome in non-diabetic patients with primary hypertension: the MAGIC study.Prevalence of abnormal urinary albumin excretion in a population-based study in Spain: results from the HERMEX Study.Uric acid, microalbuminuria and cardiovascular events in high-risk patients.Is administration of preoperative angiotensin-converting enzyme inhibitors important for renal protection after cardiac surgery?Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats.Nephrology care in Canada.Modelling diabetic nephropathy in mice.Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.Contrast media volume optimization in high-pitch dual-source CT coronary angiography: feasibility study.How important is it to control nocturnal hypertension with angiotensin II type 1 receptor blockers?Different Types of Renal Dysfunction in Patients with Acute Myocardial Infarction Treated with Percutaneous Coronary Intervention
P2860
Q24202090-D5BCF084-1752-473D-861A-70D7863B62FCQ24242191-A95F1DF0-DAF6-4168-A98B-DCFB277CAC74Q24242944-B8B792D8-B10F-442D-BC62-D9D5C278F298Q24245704-F02A3642-7991-44A0-A4EB-587060C6F565Q28188518-BBFFC1E0-8130-4DED-88C3-9F931FA884F9Q28595982-B15DC20E-5FB5-4F6C-AE93-B0787D76AC55Q33570908-7AC13DBB-DF98-4F1A-8584-56C922274173Q33888381-E90975F3-375B-453C-A78C-D9FA3A1A9387Q34215485-E1689FDA-92E5-48BE-A107-56E7980FD28FQ34240922-C6FCBDFD-6FF5-4BD4-88C2-6E61CC2AFAC8Q34453230-AD0714F4-DC14-40F6-9C96-D2FD6469DF53Q34959486-0D2F8A3E-C726-4733-A8C7-9F3AA7823CEAQ35025425-DED21408-019A-436B-9D92-99E24EAC54A7Q35648485-E21C5CF6-515D-4CD8-8688-3F6F89309235Q35990779-517B83C7-BCBF-40D7-B1BA-B9D7F36639BDQ36191289-E0D4C64D-49BE-4044-9ED8-695D20E69518Q36675029-9C4AE4BE-D8EA-4FCC-ADAC-206BC38C20F5Q37188464-4D33116C-B23B-42A2-A0F6-F440A15D7E63Q37427247-0B82A24D-B87C-44D7-A65E-75709BE49930Q37463910-1BF851FB-D141-4CBE-8604-F88134478146Q37492556-0CCB3638-5002-429C-931F-E7B730181155Q37566053-97E5A21D-699B-4FCE-963A-821DEDEC51C5Q37886063-2DF495F8-4C1D-4EED-84B1-EBD1F6F9B0B1Q38055501-1031C05D-32DE-42E4-BDED-50921568AE65Q44038990-9F7C59EF-70B4-438C-BD7D-8874842134D5Q44474115-F4BF8813-A495-4DF6-8665-5B900BBD59A2Q45277205-89267BF4-ABA1-4BE8-8848-4C020AB550C8Q45904485-5C78FB4B-EEF7-47BF-9DBB-B8C5ED7EC982Q46575615-88AA977E-47CB-4A40-8085-29139D57F664Q47102175-A2FB7210-7EFB-46F3-AD1A-50376DF87AC9Q47735079-F0C489F9-C5C7-4586-B872-959AA5755823Q48347744-4646424F-F1FE-437A-8CC2-28F29FCA8222Q51364800-E8E2A2DD-6CC3-4B2D-A870-6505D77F8BC4Q53962998-BEC7F31F-BE03-4708-B66B-FB1F988F08AFQ58819431-369DEFB1-4073-4196-B52C-2C32E9E5F9CB
P2860
Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Development of renal disease i ...... of the HOPE randomized study.
@en
Development of renal disease i ...... of the HOPE randomized study.
@nl
type
label
Development of renal disease i ...... of the HOPE randomized study.
@en
Development of renal disease i ...... of the HOPE randomized study.
@nl
prefLabel
Development of renal disease i ...... of the HOPE randomized study.
@en
Development of renal disease i ...... of the HOPE randomized study.
@nl
P2093
P1476
Development of renal disease i ...... of the HOPE randomized study.
@en
P2093
Andrew Rashkow
Byron J Hoogwerf
Eva M Lonn
Johannes F E Mann
Qi-Long Yi
P304
P356
10.1097/01.ASN.0000051594.21922.99
P577
2003-03-01T00:00:00Z